Sunday, August 14, 2022

A new test for COVID allows us to differentiate between immunity generated by infection and immunity provided by vaccines

File image of analysis of PCR tests in the laboratory to detect the presence of SARSCoV-2 coronavirus.

Those responsible for the study highlight that this PCR test could be used in making potential public health decisions, such as vaccination strategy.

In order to make potential public health decisions, such as a vaccination strategy against COVID-19, it is important to know how long the immune system’s protection against the virus persists after the infection has passed and the safety of vaccines against the disease. How long does it last? Even more so when there is already a date for the fourth dose of the vaccine.

A team from the Carlos III Health Institute’s (ISCIII) National Center for Microbiology, together with scientists from Mount Sinai Hospital in New York and the Duke School of Medicine in Singapore, has created an investigation that has allowed the evolution of the microbiology. A new test that allows these variables to be measured. And not only that, this pioneering trial makes it possible to differentiate the immune response to vaccination against COVID-19 from the immune response caused by infection by the virus.

Read Also:  Canada allows non-essential travel for fully vaccinated Americans

In this sense, one of the authors of the work, scientists from the ISCIII National Microbiology Center Jordi Ochando, highlights that “thanks to its effectiveness in measuring both the functioning of our defenses against viruses and the duration of protection of vaccines . , The obtained data is important for the determination of herd immunity and the design of vaccination campaigns».

Testing is simpler and faster by performing a PCR which allows to know the results and analyze hundreds of samples in about 24 hours. In addition, it is a technology “accessible to the general population” because, as Ochando explains, “the equipment to perform PCR is available in most hospitals and research centers.”

This research is based on the identification of the CXCL10 molecule as a new biomarker of cellular immunity using large-scale sequencing techniques in people infected and vaccinated with SARS-CoV-2. Using polymerase chain reaction (PCR) technology, “the study demonstrates the potential to quickly, easily and inexpensively measure the cellular response from a large number of samples,” ISCIII states in a press release.

Read Also:  Exercise may protect brain volume by keeping insulin, BMI levels low: Study

Study participants also appreciate that data on cellular immunity can quickly and easily complement information on another type of immunity, the so-called humoral immunity provided by antibodies, for which there is more data. . They explain that “while humoral, antibody-associated immunity may be less durable, cellular immunity conferred by a type of immune cell called lymphocytes may be associated with more durable and long-term protection.”

The research, published June 13 in the journal Nature Biotechnology, has been developed in collaboration with various health research institutions accredited by ISCIII, such as those associated with the hospitals of La Paz, Gregorio Maranone or 12 October.

Nation World News Desk
Nation World News Desk
Nation World News is the fastest emerging news website covering all the latest news, world’s top stories, science news entertainment sports cricket’s latest discoveries, new technology gadgets, politics news, and more.
Latest news
Related news
- Advertisement -